Skip to content

Price / book at other companies

Pfizer logo
PfizerPFE
1.8×+0.2×
Cencora logo
CencoraCOR
18×-35.2×
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
2.6×+0.8×
AbbVie logo
AbbVieABBV
261×+221×
Viatris logo
ViatrisVTRS
1.1×+0.4×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
3.9×-0.5×

Other financials

Income statement

See full
Revenue$722.5M+3.9%
Gross profit$320.1M+25.1%
Operating income$141.8M+41.3%
Net income$62.3M+411%
EPS (diluted)$0.19+375%

Balance sheet

See full
Cash & equivalents$197.7M+234%
Total debt$2.6B+17.7%
Total equity-$45.4M+65.5%
Total assets$3.5B+5.2%

Cash flow

See full
Operating cash flow-$26.7M-461%
CapEx$8.2M-37.9%
Free cash flow-$34.9M-507%

Valuation

See full
Market cap$5.17B+51.0%
Enterprise value$7.55B+33.4%
P/E42.4×
P/S1.7×+0.5×

Profitability

See full
Gross margin38.7%+2.0pp
Operating margin14.3%+1.6pp
Net margin4%+3.6pp
FCF margin7.9%-1.0pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity127.9×+119×
Current ratio2.5×+1.1×

Where this comes from

Calculated from Amneal Pharmaceuticals, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Amneal Pharmaceuticals, Inc.’s 10-K, filed February 27, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amneal Pharmaceuticals, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amneal Pharmaceuticals, Inc.'s price / book?
Amneal Pharmaceuticals, Inc. (AMRX) reported price / book of 94.1× in Q4 2023.
How has Amneal Pharmaceuticals, Inc.'s price / book changed year-over-year?
Amneal Pharmaceuticals, Inc.'s price / book increased by 9212.6% year-over-year, from 1× to 94.1×.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s price / book?
Over 3 years (2020 to 2023), Amneal Pharmaceuticals, Inc.'s price / book has grown at a 247.0% compound annual growth rate (CAGR), from 2.3× to 94.1×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.